| [1] |
Pinsky PF, Kramer BS. Lung cancer risk and demographic characteristics of current 20-29 pack-year smokers: Implications for screening[J]. J Natl Cancer Inst, 2015, 107(11): djv226.
|
| [2] |
Kim DD, Cohen JT, Wong JB, et al. Targeted incentive programs for lung cancer screening can improve population health and economic efficiency[J]. Health Aff (Millwood), 2019, 38(1):60-67.
|
| [3] |
O'Brien TD, Jia P, Aldrich MC, et al. Lung cancer: One disease or many[J]. Hum Hered, 2018, 83(2):65-70.
|
| [4] |
He W, Xu D, Wang Z, et al. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage Ⅲ/Ⅳ lung adenocarcinoma[J]. J Transl Med, 2019, 17(1):32.
|
| [5] |
Ma Y, Fan M, Dai L, et al. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment[J]. Tumour Biol, 2015, 36(10):8085-8092.
|
| [6] |
Xie L, Dang Y, Guo J, et al. High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients[J]. Genes (Basel), 2019, 10(1):36.
|
| [7] |
Zhou X, Cai L, Liu J, et al. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma[J]. Oncol Lett, 2018, 16(1):362-370.
|
| [8] |
Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma[J]. Expert Rev Mol Diagn, 2016, 16(7):737-749.
|
| [9] |
Li SD, Martial A, Schrock AB, et al. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma[J]. Exp Hematol Oncol, 2017, 6:29.
|
| [10] |
Chen JH, Wang YY, Lv WB, et al. Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort[J]. World J Gastroenterol, 2016, 22(16):4183-4190.
|
| [11] |
Xu H, Choe C, Shin SH, et al. Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma[J]. Exp Mol Med, 2014, 46(5):e97.
|
| [12] |
Yang Z, Li C, Yan C, et al. KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(1):181-192.
|
| [13] |
Li ZY, Wang ZX, Li CC. Kinesin family member 20B regulates tongue cancer progression by promoting cell proliferation[J]. Mol Med Rep, 2019, 19(3):2202-2210.
|
| [14] |
De Wever V, Nasa I, Chamousset D, et al. The human mitotic kinesin KIF18A binds protein phosphatase 1 (PP1) through a highly conserved docking motif[J]. Biochem Biophys Res Commun, 2014, 453(3):432-437.
|
| [15] |
Kasahara M, Nagahara M, Nakagawa T, et al. Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer[J]. Oncol Lett, 2016, 12(3):1909-1914.
|
| [16] |
Yang F, Chen Y, Dai W. Sumoylation of Kif18A plays a role in regulating mitotic progression[J]. BMC Cancer, 2015, 15:197.
|
| [17] |
Li G, Xie ZK, Zhu DS, et al. KIF20B promotes the progression of clear cell renal cell carcinoma by stimulating cell proliferation[J]. J Cell Physiol, 2019, doi: 10.1002/jcp.28322. |
| [18] |
Tomei EJ, Wolniak SM. Kinesin-2 and kinesin-9 have atypical functions during ciliogenesis in the male gametophyte of Marsilea vestita[J]. BMC Cell Biol, 2016, 17(1):29.
|
| [19] |
MacDonald JI, Dietrich A, Gamble S, et al. Nesca, a novel neuronal adapter protein, links the molecular motor kinesin with the pre-synaptic membrane protein, syntaxin-1, in hippocampal neurons[J]. J Neurochem, 2012, 121(6):861-880.
|
| [20] |
Rath O, Kozielski F. Kinesins and cancer[J]. Nat Rev Cancer, 2012, 12(8):527-539.
|
| [21] |
Zhang C, Zhu C, Chen H, et al. Kif18A is involved in human breast carcinogenesis[J]. Carcinogenesis, 2010, 31(9):1676-1684.
|
| [22] |
Czechanski A, Kim H, Byers C, et al. Kif18a is specifically required for mitotic progression during germ line development[J]. Dev Biol, 2015, 402(2):253-262.
|
| [23] |
Shin Y, Du Y, Collier SE, et al. Biased Brownian motion as a mechanism to facilitate nanometer-scale exploration of the microtubule plus end by a kinesin-8[J]. Proc Natl Acad Sci USA, 2015, 112(29):E3826-3835.
|
| [24] |
Chen QI, Cao B, Nan N, et al. Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma[J]. Exp Ther Med, 2016, 12(1):377-383.
|
| [25] |
Zhu H, Xu W, Zhang H, et al. Targeted deletion of Kif18a protects from colitis-associated colorectal (CAC) tumors in mice through impairing Akt phosphorylation[J]. Biochem Biophys Res Commun, 2013, 438(1):97-102.
|
| [26] |
Luo W, Liao M, Liao Y, et al. The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma[J]. World J Surg Oncol, 2018, 16(1):36.
|
| [27] |
Motono N, Funasaki A, Sekimura A, et al. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma[J]. Med Oncol, 2018, 35(3):22.
|
| [28] |
Liu C, Li Z, Wang S, et al. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma[J]. J Cancer Res Clin Oncol, 2019, 145(1):65-76.
|
| [29] |
Cross RA, McAinsh A. Prime movers: the mechanochemistry of mitotic kinesins[J]. Nat Rev Mol Cell Biol, 2014, 15(4):257-271.
|
| [30] |
Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy[J]. Cell Mol Life Sci, 2005, 62(24):3039-3056.
|
| [31] |
Du Y, English CA, Ohi R. The kinesin-8 Kif18A dampens microtubule plus-end dynamics[J]. Curr Biol, 2010, 20(4):374-380.
|